Skip to content

BETTERLIFE PHARMA INC.: 10-Q filed 2015-06-17

What BETTERLIFE PHARMA INC. reported in its quarterly report filed 2015-06-17 (fiscal Q1 2016): 20 published measures, 40 facts as tagged in accession 0001477932-15-003908.

This filing

Form
10-Q (quarterly report)
Filed
2015-06-17
Fiscal period
fiscal Q1 2016
Accession
0001477932-15-003908 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BETTERLIFE PHARMA INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2015-04-3035,021CAD
At 2015-01-311,610CAD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2015-04-3095,005CAD
At 2015-01-3171,053CAD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2015-04-30-59,984CAD
At 2015-01-31-69,443CAD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2015-04-3033,784CAD
At 2015-01-311,067CAD
At 2014-04-30480CAD
At 2014-01-311,044CAD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2015-02-01 to 2015-04-30-1,457,589CAD89
2014-02-01 to 2014-04-3090,764CAD89

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2015-02-01 to 2015-04-30-16,127CAD89
2014-02-01 to 2014-04-30-564CAD89

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2015-02-01 to 2015-04-3048,844CAD89

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2015-04-30-5,628,883CAD
At 2015-01-31-4,171,294CAD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2015-02-01 to 2015-04-3072,649,160shares89
2014-02-01 to 2014-04-3010,144,123shares89

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2015-02-01 to 2015-04-30-0.02CAD/shares89
2014-02-01 to 2014-04-300.01CAD/shares89

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2015-02-01 to 2015-04-30-0.02CAD/shares89
2014-02-01 to 2014-04-300.01CAD/shares89

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2015-04-30303CAD
At 2015-01-31417CAD

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2015-04-3034,718CAD
At 2015-01-311,193CAD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2014-02-01 to 2014-04-309,071CAD89

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2015-04-30934CAD
At 2015-01-31126CAD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2015-02-01 to 2015-04-301,446,602CAD89
2014-02-01 to 2014-04-308,194CAD89

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2015-04-3078,763,767shares
At 2015-01-3165,863,766shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2015-04-30267,586CAD
At 2015-01-31267,586CAD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2015-02-01 to 2015-04-303,743CAD89
2014-02-01 to 2014-04-303,439CAD89

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2015-02-01 to 2015-04-30114CAD89
2014-02-01 to 2014-04-30114CAD89

Inspect the source

Entity
BETTERLIFE PHARMA INC. / CIK 0001464165
Captured
2026-09-20T09:06:34.124Z
SEC response SHA-256
da89258f023cbc29ad1ecdd31014873fa96a7739fba3e7b66a8b80f8715d36cf

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001464165.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))